Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.

Idanna Innocenti, Francesco Autore, Stefania Ciolli, Francesca Romana Mauro, Donato Mannina, Giovanni Del Poeta, Giovanni D’Arena, Massimo Massaia, Marta Coscia, Stefano Molica, Gabriele Pozzato, Dimitar G. Efremov, Roberto Marasca, Pietro Galieni, Antonio Cuneo, Sonia Orlando, Alfonso Piciocchi, Riccardo Boncompagni, Donatella Vincelli, Anna Marina LiberatiFilomena Russo, Robin Foa

Risultato della ricerca: Contributo in rivistaArticolo in rivista

8 Citazioni (Scopus)

Abstract

First-line treatment for young/fit patients with chronic lymphocytic leukemia (CLL) is the combination of flu- d arabine, cyclophosphamide and rituximab (FCR), which has improved these patients’ progression-free survival a nd overall survival, 1 b ut is poorly tolerated by elderly patients or patients with comorbidities. 2 Such patients have been historically treated with chlorambucil, which is well tolerated but does not improve survival. 3 To improve outcomes, chlorambucil has been combined with anti-CD20 monoclonal antibodies. Three prospec- tive studies 4-6 and one retrospective 7 one investigated the combination of chlorambucil with rituximab (Chl-R) as front-line treatment for elderly CLL patients or for younger patients unsuitable for fludarabine-based thera- pies. Overall response rates ranging from 66% to 84% have been reported, with complete response rates of 8- 26% and progression-free survival from 16.3 to 34.7 months
Lingua originaleEnglish
pagine (da-a)352-355
Numero di pagine4
RivistaHaematologica
Stato di pubblicazionePubblicato - 2017
Pubblicato esternamente

Keywords

  • CLL

Fingerprint

Entra nei temi di ricerca di 'Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification.'. Insieme formano una fingerprint unica.

Cita questo